Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene.
(read here…)

People who looked at this item also looked at…

• Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation (News-Medical-Net)
• Make-up cover-up: Aussie women ‘guinea pigs’ (WA Today)
• REMINDER: Lanny L. Lewyn, Tanner EDA Technical Advisor, Presents on Nanoscale Analog CMOS Design and Shortening … (Marketwire via Yahoo! Finance)
• The Relative Size of Things (Discovery Channel)
• Enable IPC Corporation’s SolRayo Offers Three Series of Customizable Potentiostats — Exceptional Value Systems … (Marketwire)

Related items

• OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries (News-Medical-Net)
• Medivir AB announces license agreement with Daewoong Pharmaceutical for MIV-210 drug (News-Medical-Net)
• World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center (News-Medical-Net)
• ‘Smart’ nanocapsule delivery system created for use in protein therapy (Science Daily)
• Rexahn, TheraTarget form nano science research collaboration (PharmaBiz)

Tags: Agios, cancer, enzyme activity, Gene, nano, nanotech, nanotechnology, novel enzyme, oncogene, Pharmaceuticals, Technology, time, today, today announced that

This entry was posted on November 24, 2009 at 1:54 pm and is filed under Technology.